ArticleScientific reports2026
D-serine and D-alanine supplementation protects against chronic kidney disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gut Microbiota and Their Metabolites in Acute Kidney Injury: Classification, Mechanisms, and Therapeutic Potential.Metabolites · 2026Review
- Amino acid homeostasis in the kidney: Physiological roles and pathological dysregulation.Physiological reports · 2026Review
- A multi-organ spatial metabolomic atlas of exercising mice reveals neuronal Complex I as a convergent and sufficient axis for tau pathology reduction in PS19.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Novel therapeutic targets for renal protection are imperative due to the escalating prevalence of end-stage kidney disease despite existing treatments for chronic kidney disease (CKD). We explored the reno-protective effects of D-serine and D-alanine, which have previously demonstrated efficacy in acute kidney injury against CKD. Female and male 5/6-nephrectomy mice were used as CKD models, receiving 20 mM D-serine or D-alanine supplementation, and their survival rates, renal function, and transcriptomic changes were examined. The proliferation of human tubular epithelial cells supplemented with D-serine or D-alanine was evaluated in vitro. A prospective cohort study involving 14 patients was conducted to examine the association between increased blood D-serine or D-alanine levels and long-term renal function decline. D-serine or D-alanine supplementation improved survival rates and renal function in female 5/6-nephrectomy mice. D-alanine supplementation was associated with the upregulation of mitochondrial pathway-related genes. Long-term supplementation (500 days) in normal mice did not induce nephrotoxicity, and promoted tubular epithelial cell proliferation. Although a trend toward a slower decline in eGFR was observed in patients with higher D-alanine levels, this association was limited and does not indicate a causal relationship. Further studies involving D-Ala interventions in patients with CKD are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.